dinaciclib and Lymphoma--B-Cell

dinaciclib has been researched along with Lymphoma--B-Cell* in 1 studies

Other Studies

1 other study(ies) available for dinaciclib and Lymphoma--B-Cell

Article	Year
CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Leukemia, 2015, Volume: 29, Issue:6 Topics: Animals; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cells, Cultured; Cyclic N-Oxides; Cyclin-Dependent Kinase 9; Fibroblasts; Humans; Indolizines; Lymphoma, B-Cell; Mice; Mice, Inbred C57BL; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-myc; Pyridinium Compounds	2015

Article

Year

CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.

Leukemia, 2015, Volume: 29, Issue:6

Topics: Animals; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cells, Cultured; Cyclic N-Oxides; Cyclin-Dependent Kinase 9; Fibroblasts; Humans; Indolizines; Lymphoma, B-Cell; Mice; Mice, Inbred C57BL; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-myc; Pyridinium Compounds

2015